Cell Therapy News Volume 25.34 | Nov 4 2024

    0
    138







    2024-11-04 | CTN 25.34


    Cell Therapy News by STEMCELL Technologies
    Vol. 25.34 – 4 November, 2024
    TOP STORY

    Large DNA Deletions Occur during DNA Repair at 20-Fold Lower Frequency for Base Editors and Prime Editors than for Cas9 Nucleases

    Scientists showed that Cas9-mediated double-strand breaks induced large deletions at varying frequencies in cancer cell lines, human embryonic stem cells, and human primary T cells, and that most deletions were produced by two repair pathways.
    [Nature Biomedical Engineering]

    Full Article
    Who does immunology research in the Bolivian Andes? He does. Read Jason Young's story.
    PUBLICATIONSListed by the impact factor of the journal

    Human iPSC-Derived Neural Stem Cells Displaying Radial Glia Signature Exhibit Long-Term Safety in Mice

    The authors demonstrated that hiPSC-neural stem/progenitor cells adopted a radial glia-associated signature, sharing key epigenetic and transcriptional characteristics with human fetal neural stem cells while exhibiting divergent profiles from glioblastoma stem cells.
    [Nature Communications]

    Full Article

    PD-1+CD8+ T Cell-Mediated Hepatocyte Pyroptosis Promotes Progression of Murine Autoimmune Liver Disease

    Researchers identified a specific expanded pathogenic subset of PD-1+CD8+ T cells in the liver, exhibiting strong functional activity and cytotoxicity against target cells.
    [Advanced Science]

    Full Article

    Integrative Single-Cell Multi-Omics of CD19-CARpos and CARneg T Cells Suggest Drivers of Immunotherapy Response in B Cell Neoplasias

    Scientists integrated clonal kinetics with transcriptomic heterogeneity resolved by single-cell omics to interrogate cellular dynamics of non-transduced (CARneg) and transduced T cells (CARpos).
    [Cell Reports Medicine]

    Full ArticleGraphical Abstract

    Characterization of RNA Editing and Gene Therapy with a Compact CRISPR-Cas13 in the Retina

    Investigators reported significant transcriptomic signatures of Cas13bt3 expression in retinal cells and show all-in-one adeno-associated virus gene therapy with Cas13bt3 can effectively silence VEGFA mRNA in human retinal organoids and humanized VEGF transgenic mouse models.
    [Proceedings of The National Academy of Sciences of The United States of America]

    Abstract

    Engraftment of a Surrogate Antigen onto Tumor Cell Surface via pHLIP Peptide to Universally Target CAR-T Cell Therapy to Solid Tumors

    The authors evaluated the efficiency of Myc-pH-low insertion peptide (pHLIP) in inserting the artificial c-Myc-tag onto the plasma membrane of malignant cells and determined if this engraftment could convert it into a therapeutic target for CAR-T cells or monoclonal antibodies.
    [Cancer Letters]

    Full Article

    Phenotypic Insights into Genetic Risk Factors for Immune-Related Adverse Events in Cancer Immunotherapy

    Utilizing publicly accessible genome-wide association study data, this investigation evaluated the impact of over 5000 exposure variables on susceptibility to immune-related adverse events using univariate Mendelian randomization.
    [Cancer Immunology Immunotherapy]

    Full Article

    Synergistic Effects of Human Umbilical Cord Mesenchymal Stem Cells/Neural Stem Cells and Epidural Electrical Stimulation on Spinal Cord Injury Rehabilitation

    Scientists examined neural stem cell changes via mRNA sequencing in an in vitro Transwell co-culture model. They then explored cell interaction mechanisms using proliferation assays, differentiation assays, and neuron complexity analysis.
    [Scientific Reports]

    Full Article

    Intracavernosal Mesenchymal Stem Cell Therapy in Ischemic Priapism: An Experimental Study

    30 male Wistar albino rats were divided into three groups: sham, priapism, and priapism + mesenchymal stem cell treatment. The experimental groups were also divided into 1 and 12 hour subgroups of ischemic priapism.
    [International Urology and Nephrology]

    Abstract

    Banner Ad Cross Reference Banner Ad Cross Reference 100% 10 E17 Visit the Hematopoiesis Resource Center for videos, tips, and protocols to help with your research questions. Screen reader support enabled. Visit the Hematopoiesis Resource Center for videos, tips, and protocols to help with your research questions. Turn on screen reader support
    REVIEWS

    CAR T Cells and T Cell Therapies for Cancer

    CAR T-cell therapy is an FDA-approved therapy that has improved progression-free survival for multiple myeloma, improved overall survival for large B-cell lymphoma, and attained high rates of cancer remission for other hematologic malignancies.
    [Jama-Journal of The American Medical Association]

    Abstract

    Focusing on Exosomes to Overcome the Existing Bottlenecks of CAR-T Cell Therapy

    Investigators delve into the effect of tumor-derived exosomes on the CAR-T cell function and discuss how inhibiting their secretion can enhance the efficacy of CAR-T cell therapy.
    [Inflammation and Regeneration]

    Full Article

    Navigating the Roadblocks: Progress and Challenges in Cell-Based Therapies for Human Immunodeficiency Virus

    The authors address the challenges to cell-based therapies against HIV and discuss the recent advancements aimed at overcoming them.
    [Journal of Cellular Biochemistry]

    Abstract
    INDUSTRY AND POLICY NEWS

    Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ALLO-316, an AlloCAR Tâ„¢ Investigational Product for Adult Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)

    Allogene Therapeutics, Inc. announced that the US FDA granted RMAT designation to ALLO-316 for the treatment of adult patients with CD70 positive advanced or metastatic renal cell carcinoma.
    [Allogene Therapeutics, Inc. (GlobenewsWire)]

    Press Release

    ‘It Was a Good Lesson’: FDA Reconsiders CAR-T Boxed Warning on Secondary Cancers, Peter Marks Says

    An FDA announcement last year led to classwide black boxed warnings on existing CAR-T products’ labels. Now FDA is reconsidering those serious safety warnings with plans to change them potentially, Dr. Peter Marks, said in an interview with Fierce Pharma.
    [Fierce Pharma]

    News Article

    SSF Funds Industrial for PhD Student Aishe Sarshad in Collaboration with AstraZeneca

    The PhD project, has been awarded 3.25 million SEK from the Swedish Foundation for Strategic Research (SSF), will explore how small RNA molecules can be used to activate specific genes. AstraZeneca is providing additional funding, ensuring that the entire PhD project is fully financed for four years.
    [University of Gothenburg]

    Press Release
    FEATURED EVENT

    Cell Therapy Analytical Development Summit

    December 3-5, 2024
    Boston, Massachusetts, United States

    > See All Events

    JOB OPPORTUNITIES

    Research Assistant – Innate Cell Therapy

    Baylor College of Medicine – Houston, Texas, United States

    Postdoctoral Research Fellow – Multiple Myeloma

    Hackensack Meridian Health – CDI – Nutley, New Jersey, United States

    Postdoctoral Fellow – Stem Cell Transplantation and Regenerative

    Stanford University – Stanford, California, United States

    Research Assistant – Gene Therapy for Rare Epilepsy

    University College London – London, England, United Kingdom

    PhD Studentship – Hematopoietic Specification

    Norwich Bioscience Institutes – Norwich, England, United Kingdom

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2